YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line

Oncology Reports

Volumn 32, Issue 1, 2014, Pages 159-166

  Akiyama, Yasuto ^a   Ashizawa, Tadashi ^a   Komiyama, Masaru ^a   Miyata, Haruo ^a   Oshita, Chie ^a   Omiya, Maho ^a   Iizuka, Akira ^a   Kume, Akiko ^a   Sugino, Takashi ^a   Hayashi, Nakamasa ^a   Mitsuya, Koichi ^a   Nakasu, Yoko ^a   Yamaguchi, Ken ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Recurrent glioblastoma; shRNA; STAT3; TMZ resistance; YKL 40

Indexed keywords

MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; SHORT HAIRPIN RNA; STAT3 PROTEIN; TEMOZOLOMIDE; ADIPOCYTOKINE; CHI3L1 PROTEIN, HUMAN; DACARBAZINE; LECTIN; MAGEC1 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG SENSITIVITY; DRUG TARGETING; GENE; GENE EXPRESSION REGULATION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SURVIVAL TIME; TUMOR INVASION; UPREGULATION; YKL 40 GENE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ADIPOKINES; ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; LECTINS; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903205317     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3195     Document Type: Article

References (34)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. (Pubitemid 40349501)
2. Mirimanoff RO, Gorlia T, Mason W, et al: Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24: 2563-2569, 2006. (Pubitemid 46630635)
3. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S and Sobol RW: The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 65: 6394-6400, 2005. (Pubitemid 40994427)
4. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005. (Pubitemid 40349502)
5. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 23: 7178-7187, 2005.
6. 6-benzylguanine in adults with recurrent, temozolomide- resistant malignant glioma. J Clin Oncol 27: 1262-1267, 2009.
7. Murat A, Migliavacca E, Gorlia T, et al: Stem cell-related 'self-renewal' signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26: 3015-3024, 2008.
8. Hunter C, Smith R, Cahill DP, et al: A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66: 3987-3991, 2006.
9. Sun S, Lee D, Ho AS, et al: Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. Neuro Oncol 15: 562-577, 2013.
10. Mukherjee B, McEllin B, Camacho CV, et al: EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 69: 4252-4259, 2009.
11. Kitange GJ, Carlson BL, Schroeder MA, et al: Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. J Neurooncol 100: 177-186, 2010.
12. Vlachostergios PJ, Hatzidaki E, Befani CD, Liakos P and Papandreou CN: Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner. Invest New Drugs 31: 1169-1181, 2013.
13. Kanzawa T, Germano IM, Kondo Y, Ito H, Kyo S and Kondo S: Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br J Cancer 89: 922-929, 2003. (Pubitemid 37175817)
14. 6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther 7: 3842-3851, 2008.
15. Jiang G, Wei ZP, Pei DS, Xin Y, Liu YQ and Zheng JN: A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. Biochem Biophys Res Commun 406: 311-314, 2011.
16. Tso CL, Shintaku P, Chen J et al: Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res 4: 607-619, 2006. (Pubitemid 44497214)
17. Phillips HS, Kharbanda S, Chen R, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173, 2006. (Pubitemid 43357943)
18. Carro MS, Lim WK, Alvarez MJ, et al: The transcriptional network for mesenchymal transformation of brain tumors. Nature 463: 318-325, 2010.
19. Verhaak RG, Hoadley KA, Purdom E, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110, 2010.
20. Ashizawa T, Miyata H, Iizuka A, et al: Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. Int J Oncol 43: 219-227, 2013.
21. Ashizawa T, Miyata H, Ishii H, et al: Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int J Oncol 38: 1245-1252, 2011.
22. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double A, Everitt J, Farningham DAH, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR and Eccles SA: An ad hoc committee of the National Cancer Research Institute: Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577, 2010.
23. Kohsaka S, Wang L, Yachi K, et al: STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther 11: 1289-1299, 2012.
24. Singh SK, Bhardwaj R, Wilczynska KM, Dumur CI and Kordula T: A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40. J Biol Chem 286: 39893-39903, 2011.
25. Kzhyshkowska J, Gratchev A and Goerdt S: Human chitinases and chitinase-like ptoteins as indicators for inflammation and cancer. Biomark Insights 3: 128-146, 2007.
26. Shao R, Hamel K, Petersen L, et al: YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 28: 4456-4468, 2009.
27. Francescone RA, Scully S, Faibish M, et al: Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem 286: 15332-15343, 2011.
28. Tanwar MK, Gilbert MR and Holland EC: Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62: 4364-4368, 2002. (Pubitemid 34827294)
29. Høgdall EV, Johansen JS, Kjaer SK, et al: High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep 10: 1535-1538, 2003.
30. Hormigo A, Gu B, Karimi S, et al: YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12: 5698-5704, 2006. (Pubitemid 44629598)
31. Thöm I, Andritzky B, Schuch G, et al: Elevated pretreatment serum concentration of YKL-40 - An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer 116: 4114-4121, 2010.
32. Zhang W, Kawanishi M, Miyake K, et al: Association between YKL-40 and adult primary astrocytoma. Cancer 116: 2688-2697, 2010.
33. Iwamoto FM, Hottinger AF, Karimi S, et al: Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol 13: 1244-1251, 2011.
34. Bernardi D, Padoan A, Ballin A, et al: Serum YKL-40 following resection for cerebral glioblastoma. J Neurooncol 107: 299-305, 2012.